Optimizerx: 15min chart triggers MACD Death Cross, Bollinger Bands Narrowing

Based on the 15-minute chart, the MACD Death Cross and narrowing Bollinger Bands at 10/20/2025 12:15 suggest that the stock price has the potential to continue declining, with a decreasing magnitude of fluctuations.

Adaptimmune Therapeutics Plc (NASDAQ: ADAP), a clinical-stage biopharmaceutical company specializing in T-cell receptor therapies for solid tumor cancers, has announced significant updates. On October 20, 2025, the company's Board authorized the voluntary delisting of its American Depositary Shares (ADSs) from Nasdaq, effective approximately 90 days after the filing of Form 25. This move is aimed at reducing costs associated with SEC reporting, Sarbanes-Oxley compliance, and Nasdaq listing requirements, following a transaction with US WorldMeds, according to a StockTitan report.

In the second quarter of 2025, Adaptimmune reported financial results that highlighted a substantial increase in revenue and cash position. The company achieved $11.1 million in Q2 Tecelra sales, representing over 150% growth compared to Q1 2025. Total revenue for Q2 2025 was $13.7 million, with a cash position of $26.1 million. Despite these gains, Adaptimmune reported a net loss of $30.3 million for the quarter. The company has entered into a $55 million upfront deal with US WorldMeds for the sale of its cell therapy portfolio, including TECELRA, lete-cel, afami-cel, and uza-cel, with potential for up to $30 million in additional milestone payments. This transaction has allowed Adaptimmune to repay its Hercules Capital debt and focus on restructuring its assets, including PRAME and CD70 directed T-cell therapies .

Adaptimmune's stock price has shown potential for continued decline, as indicated by the MACD Death Cross and narrowing Bollinger Bands on the 10/20/2025 12:15 chart. This suggests a decreasing magnitude of fluctuations in the stock price, which could be attributed to the company's restructuring efforts and financial results .